21:16 , May 6, 2019 |  BC Extra  |  Company News

Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub

Lundbeck will obtain its first pipeline candidate to treat Tourette syndrome via a deal to acquire Abide. The deal will give the Danish pharma a California-based discovery site, and could also help it implement a...
16:02 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting MGLL could help treat chemotherapy-induced neuropathic pain. In a mouse model of paclitaxel-induced neuropathic pain, two tool compound MGLL inhibitors decreased mechanical allodynia compared with vehicle. Next steps could...
00:31 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Abide begins Phase Ib trial for neuroinflammatory pain candidate ABX-1431

Abide Therapeutics Inc. (San Diego, Calif.) began a crossover Phase Ib trial of ABX-1431 to treat neuroinflammatory disorders associated with central pain. ABX-1431 is a small molecule inhibitor of monoglyceride lipase (MGLL; MAGL), which regulates...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

Abide Therapeutics, Celgene deal

Celgene exercised an option from a 2014 deal and will obtain worldwide rights outside the U.S. to Abide’s ABX-1431 . The product is in Phase Ia testing, and Abide plans to conduct additional Phase Ib...
07:00 , Sep 29, 2016 |  BC Extra  |  Company News

Celgene opts in for ex-U.S. rights to Abide compound

Celgene Corp. (NASDAQ:CELG) exercised an option giving it ex-U.S. rights to ABX-1431 from Abide Therapeutics Inc. (San Diego, Calif.). The small molecule inhibitor of monoacylglycerol lipase ( MAGL ) is in Phase I testing for...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

ABX-1431: Phase Ia started

Abide began a double-blind, placebo-controlled, Belgian Phase Ia trial to evaluate single and multiple ascending doses of ABX-1431 in about 60 healthy volunteers. Abide said potential indications include neuropathic pain, neuro-inflammation, neurodegenerative diseases and forms...
08:00 , Nov 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Abhydrolase domain containing 6 (ABHD6) Cell culture and mouse studies suggest inhibiting ABHD6 could help treat chronic inflammation. In several types of cultured lipopolysaccharide...
08:00 , Feb 13, 2012 |  BioCentury  |  Emerging Company Profile

Abide: Selecting serine hydrolases

Abide Therapeutics Inc. is developing an approach to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. Most of the new targets will require significant...
08:00 , Nov 17, 2011 |  BC Innovations  |  Cover Story

Dampening neuroinflammation

A California team has shown that monoacylglycerol lipase , which controls levels of a pain-reducing metabolite in the brain, also regulates neuroinflammation. 1 The researchers have proof of concept that a small molecule inhibitor of...
08:00 , Jan 15, 2009 |  BC Innovations  |  Targets & Mechanisms

Gift of the MAGL

A team at The Scripps Research Institute has developed the first specific monoacylglyceride lipase ( MAGL ) inhibitor, which should help determine whether this enzyme is a better pain target than the closely related fatty...